Brahma Capital is a private investment firm focused on investing in biotechnology, special situations and public markets. Founded in 2019 by Sundeep Agrawal, the firm seeks outsized returns by identifying transformative companies with proven management teams. The firm invests the personal capital of its Founder and co-invests with strategic capital partners.
Brahma Capital Outsized Returns
Our Metrics
15+ investments
Founded in 2019, we have made over 15 investments
1 sector expertise
Our investments are focused across biotech, public equities, and special situations
$10B+ value
Our portfolio has generated $10B+ in market value on the public markets
Select Investments
NASDAQ: VRNA
NASDAQ: PCVX
NASDAQ: RUM
NASDAQ: ERAS
NASDAQ: ABVX
NASDAQ: ERAS
NASDAQ: RCKT
NASDAQ: SPRY
NASDAQ: RVMD
NASDAQ: IMVT
NASDAQ: MRTX
Acquired by BMS for $5.8B in January 2024
NASDAQ: RUM
Featured News
Brahma Capital Co-Leads $84M Financing for BlossomHill Therapeutics
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline...
DECEMBER 10, 2025
Merck to Acquire Verona Pharma for Approximately $10B
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases...
JULY 30, 2025
Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives
Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation...
APRIL 03, 2024
This chemist's last startup sold for $4 billion. Now investors have poured $173 million into her next act
Jean Cui, a former Pfizer chemist whose last company was sold to Bristol Myers Squibb for $4 billion...